Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF V600E-Mutant Metastatic NSCLC (China)
CTR20200259Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in Non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Mar 2020; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200259.